Drugs / ADL5747
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01058642 | Jan → Dec 2010 | postherpetic neuralgia | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00979953 | Oct 2009 → Apr 2010 | osteoarthritis, knee | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADL5747 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00979953 ↗ |
| Known as | CHEMBL561339 | ChEMBL registry synonym — accepted as the source's own label CHEMBL561339 ↗ |
| Action | Activate | “Delta opioid receptor agonist” CHEMBL561339 ↗ |
| Modality | Small molecule | — CHEMBL561339 ↗ |
| Route | Oral | “administered orally BID for 14 days” NCT00979953 ↗ |
| Target | OPRD1 | “Delta opioid receptor agonist” CHEMBL561339 ↗ |